Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DLIT-AML: Dexamethasone with Venetoclax-based LIT in AML
NCT07014462Phase 1Enrolling by invitation
- Sponsor
- The University of Vermont
- Start
- Sep 2025
- Primary completion
- Jun 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dexamethasone in acute myeloid leukemia (AML), sponsored by The University of Vermont. Primary endpoint: Safety and tolerability of adding dexamethasone to venetoclax-based low-intensity therapy at 6 months. Started Sep 2025; status: enrolling by invitation.
02
Drugs
dexamethasone
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07014462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07014462.